This is a prospective cohort study, which aims to evaluate the effectiveness and superiority of a novel minimal residual disease-guided prognosis monitoring and adjuvant treatment in stage IIA-IIIC non-small cell lung cancer.
Written informed consent must be signed before implementing any enrollment-related procedures;
Age ≥18 years old;
Patients with histologically or cytologically confirmed stage IIA-IIIC NSCLC (International Association for the Study of Lung Cancer and American Joint Committee on Classification of Cancer, 8th Edition TNM staging)；
There is no special restriction on the source of genetic test report.
Received surgical treatment for lung tumors.
Received neoadjuvant chemotherapy or radiotherapy.
Received cellular therapy within the last 1 year.
Treated but uncontrolled diabetes, mellitus, asthma, autoimmune diseases and other chronic diseases.